US EditionIvonescimab Plus Chemo Shows Stronger NSCLC Response Than Tislelizumab Combo
- Akeso announced positive Phase III results for ivonescimab plus chemotherapy on April 22, 2025.
- The HARMONi-6 study compared this combination to tislelizumab plus chemotherapy for first-line squamous lung cancer.
- This trial enrolled 532 patients across 66 centers in China.
- Interim data showed improved progression-free survival outcomes and a similar safety profile.
Insights by Ground AI
Does this summary seem wrong?
28 Articles
28 Articles
All
Left
2
Center
10
Right
Bennington Banner+26 Reposted by 26 other sources
Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs. Tislelizumab in Combination with Chemotherapy
HONG KONG, April 22, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is both pleased and honored to announce that its global first-in-class PD-1/VEGF bispecific antibody, ivonescimab, in combination with chemotherapy, has demonstrated strongly positive results in the…
Coverage Details
Total News Sources28
Leaning Left2Leaning Right0Center10Last UpdatedBias Distribution83% Center
Bias Distribution
- 83% of the sources are Center
83% Center
L 17%
C 83%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
